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BAFF Antagonist Attenuates the Development of Skin
Fibrosis in Tight-Skin Mice
Takashi Matsushita1, Manabu Fujimoto1, Minoru Hasegawa1, Yukiyo Matsushita1, Kazuhiro Komura1,
Fumihide Ogawa2, Rei Watanabe3, Kazuhiko Takehara1 and Shinichi Sato2
The tight-skin (TSK/þ ) mouse, a genetic model for systemic sclerosis (SSc), develops cutaneous fibrosis and
autoimmunity. Although immunological abnormalities have been demonstrated in TSK/þ mice, the roles of B-
cell-activating factor belonging to the tumor necrosis factor family (BAFF), a potent B-cell survival factor, have
not been investigated. Serum BAFF levels in TSK/þ mice were examined by ELISA. Newborn TSK/þ mice were
treated with BAFF antagonist, and then skin fibrosis of 8-week-old mice was assessed. Serum BAFF levels were
significantly elevated in TSK/þ mice. Remarkably, BAFF antagonist inhibited the development of skin fibrosis,
hyper-g-globulinemia, and the autoantibody production in TSK/þ mice. The skin from TSK/þ mice showed
upregulated expressions of fibrogenic cytokines, such as IL-6 and IL-10, while BAFF antagonist significantly
suppressed them. Reciprocally, BAFF antagonist augmented antifibrogenic cytokines, such as IFN-g, in the skin
of TSK/þ mice. Furthermore, TSK/þ B cells with BAFF stimulation had a significantly enhanced ability to
produce IL-6. The results suggest that BAFF/BAFF receptor system is critical for the development of skin fibrosis
in TSK/þ mice and could be a potent therapeutical target.
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INTRODUCTION
B-cell-activating factor belonging to the tumor necrosis factor
family (BAFF), also known as BLyS, TALL-1, and THANK,
is a tumor necrosis factor (TNF) superfamily member
(TNFSF13B) best known for its role in the survival and
maturation of B cells (Mackay and Browning, 2002). BAFF is
produced by several cell types, including monocytes,
macrophages, neutrophils, dendritic cells, and T lymphocytes
(Schneider et al., 1999), and is a ligand for at least three TNF
receptor superfamily (TNFRSF) members: B-cell maturation
antigen (BCMA/TNFRSF17), transmembrane activator and
calcium-modulator and cyclophilin ligand interactor (TACI/
TNFRSF13B), and BAFF receptor (BAFF-R/BR3/TNFRSF13C)
(Gross et al., 2000; Thompson et al., 2001). All three
receptors are primarily expressed by B cells (Mackay and
Browning, 2002). Among them, BAFF-R plays the central role
in the BAFF system (Thompson et al., 2001). BAFF/BAFF-
receptor family appears to span nearly all stages of B-lineage
differentiation, ranging from the development, selection,
and homeostasis of naive primary B cells to the maintenance
of long-lived bone marrow plasma cells (O’Connor et al.,
2004). BAFF also exhibits a strong co-stimulatory function
for B-cell activation in vitro (Moore et al., 1999; Schneider
et al., 1999). Furthermore, excess BAFF rescues self-reactive
B cells from anergy, which may play a crucial role of
autoimmune induction and development (Thien et al., 2004).
Mice overexpressing BAFF exhibit elevated B-cell numbers in
spleen and lymph node and characteristics of autoimmune
diseases, including spontaneous autoantibody production, Ig
deposits in the kidneys, and glomerulonephritis (Mackay
et al., 1999; Batten et al., 2000; Khare et al., 2000). Thereby,
mice overexpressing BAFF appear to show autoimmune
phenotype similar to patients with systemic lupus erythema-
tosus (SLE). Similarly, BAFF is overexpressed in murine
models of SLE, such as NZB/NZW F1 mice (Gross et al.,
2000), which carry a polymorphism in the Blys gene (Jiang
et al., 2001). Furthermore, inhibition of BAFF by soluble
decoy receptor is successful in treating a murine model of SLE
in which serum BAFF levels were elevated (Gross et al., 2000;
Kayagaki et al., 2002; Ramanujam et al., 2006). In humans,
previous reports have shown elevated serum BAFF levels in
patients with SLE, rheumatoid arthritis, and Sjo¨gren’s
syndrome (Cheema et al., 2001; Zhang et al., 2001; Groom
et al., 2002; Stohl et al., 2003).
Systemic sclerosis (SSc, scleroderma) is a connective tissue
disease characterized by excessive extracellular matrix
deposition in the skin and visceral organs (LeRoy et al.,
1988). Although the molecular basis for SSc pathogenesis
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is unknown, hyper-g-globulinemia, polyclonal, and memory
B-cell hyperactivity, and altered B-cell homeostasis are found
in SSc patients (Fleischmajer et al., 1977; Famularo et al.,
1989; Sato et al., 2004), with B cell-associated transcripts
upregulated in lesional skin (Whitfield et al., 2003). Disease-
specific autoantibodies reactive with DNA topoisomerase I,
RNA polymerases, and fibrillin-1 further suggests that acti-
vated B cells contribute to disease pathogenesis (Steen et al.,
1988; Kuwana et al., 1993; Tan et al., 1999). Furthermore,
anti-fibrillin-1 autoantibodies could have pathogenic role in
SSc via fibroblast activation (Zhou et al., 2005). Recently, we
have shown elevated serum levels of BAFF in SSc patients.
Serum BAFF levels were associated with skin fibrosis, and B
cells from SSc patients exhibited more enhanced responses by
BAFF stimulation (Matsushita et al., 2006). These results
suggest that BAFF and its signaling in B cells contribute to B-
cell abnormalities and disease development in SSc.
The tight-skin (TSK/þ ) mouse serves as a model for SSc
(Green et al., 1976), with increased synthesis and accumula-
tion of collagen and other extracellular matrix proteins in the
skin (Jimenez et al., 1986). Homozygous mice die in utero,
whereas heterozygous TSK/þ mice survive but develop skin
fibrosis (Osborn et al., 1983). A tandem duplication within
the fibrillin-1 gene causes tissue hyperplasia and the SSc-like
phenotype (Siracusa et al., 1996). However, there is also an
immunological component to disease pathogenesis since
CD4þ T cells, mast cells, and other immunocompetent cells
contribute to skin fibrosis in TSK/þ mice (Bocchieri et al.,
1993; Phelps et al., 1993; Wallace et al., 1994; Everett et al.,
1995). For example, the infusion of bone marrow and spleen
cells from TSK/þ mice into normal mice induces a TSK-like
cutaneous phenotype and autoantibodies (Phelps et al.,
1993). Specifically, type 2 cytokines, such as IL-4, IL-6,
IL-10, and IL-13, contribute specifically to the fibrotic
processes in scleroderma (Ong et al., 1999; McGaha et al.,
2001; Bhogal et al., 2005). By contrast, type 1 cytokines
inhibits skin sclerosis in TSK/þ mice (Tsuji-Yamada et al.,
2001; Shen et al., 2005). TSK/þ B cells also display a hyper-
responsive phenotype, with enhanced CD19-induced
[Ca2þ ]i responses, higher levels of CD19 tyrosine phosphor-
ylation (Saito et al., 2002), impaired CD22 regulation of
signal transduction (Asano et al., 2004), and the production of
autoantibodies against SSc-specific target autoantigens such
as topoisomerase I, RNA polymerase I, and fibrillin-1. There
is also a correlation between the concentration of serum anti-
topoisomerase I autoantibodies in TSK/þ mice and histo-
logical and biochemical alterations in the skin (Hatakeyama
et al., 1996). Thereby, CD19-deficiency in TSK/þ mice
downregulates B-cell function, improves skin sclerosis, and
inhibits autoimmunity (Hatakeyama et al., 1996; Saito et al.,
2002). Thus, B cell is critical not only for induction of
autoantibodies, but also for the development of skin fibrosis.
To assess directly roles of BAFF in TSK/þ mice, TSK/þ
mice were examined serum BAFF levels and BAFF-receptor
expression and treated with BAFF antagonist. The current
study suggests that BAFF significantly contributes to the
development of skin fibrosis and could be a potent
therapeutical target.
RESULTS
Elevated serum BAFF levels in TSK/þ mice
Dysregulation of serum BAFF levels in lupus-prone NZB/
NZW F1 mice has been demonstrated. Serum BAFF levels in
NZB/NZW F1 mice gradually increase with growth and are
abundant during the onset (after 20 weeks of age) and
progression of SLE (Gross et al., 2000). First, to determine
whether/when serum BAFF levels are increased in TSK/þ
mice, serum BAFF levels were measured by ELISA kit. Serum
BAFF levels were significantly higher in TSK/þ mice than
wild-type littermates until 8 weeks of age (Figure 1a). In
contrast, a significant increase of serum BAFF levels was
apparent in NZB/NZW F1 mice compared with wild-type
mice at 12 weeks of age (Figure 1a). We also examined the
expression of three BAFF-receptors on B cells in TSK/þ mice
using flow cytometry. The expression levels of BAFF-R, TACI,
and BCMA on B cells were similar between TSK/þ and wild-
type littermates (Figure 1b). Thus, the dysregulated expression
of BAFF, but not BAFF-receptors, was observed in TSK/þ
mice.
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Figure 1. BAFF is increased in sera from TSK/þ and NZB/NZW F1 mice.
(a) Serum BAFF levels were determined by ELISA. Horizontal bars represent
mean serum BAFF level in each group. *Po0.01, **Po0.05 versus wild type.
(b) Representative expression of BAFF-R, including BAFF-receptor, TACI, and
BCMA, on B220þ B cells from 8-week-old TSK/þ and wild-type littermates.
Three BAFF-receptor expressions were assessed by two-color
immunofluorescence with flow cytometric analysis. Shaded regions in
the histograms represent TSK/þ B220þ B cells, boldface lines represent
wild-type B220þ B cells, and dotted lines represent isotype control staining.
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BAFF antagonist reduces the development of skin fibrosis in
TSK/þ mice
To determine whether BAFF/BAFF-receptor interactions affect
skin fibrosis in TSK/þ mice, we administrated BAFF-R-Ig,
which neutralize BAFF, or Fc control protein into 1-week-old
TSK/þ mice thrice a week for 7 weeks. Skin fibrosis was
assessed by histopathology of full-thickness skin sections
from the back in 8-week-old TSK/þ and wild-type litter-
mates. The dermal thickness (the thickness from the top of the
granular layer to the junction between the dermis and
subcutaneous fat) was similar among each strain (data not
shown), consistent with previous reports (Green et al., 1976;
Wallace et al., 1994). The hypodermal thickness in 8-week-
old TSK/þ mice treated with control protein was increased
byB6-fold compared with wild-type littermates (Po0.0001,
Figure 2a and b). There was no significant difference in the
hypodermal thickness between the treatments with BAFF-R-Ig
and control protein in wild-type mice (Figure 2a and b).
Remarkably, 8-week-old TSK/þ mice with BAFF-R-Ig treat-
ment showed decreased hypodermal thickness that was
significantly 49% thinner than that found in TSK/þ
littermates with control protein (Po0.0001, Figure 2a and b).
Cutaneous fibrosis was also assessed by quantifying the
collagen content of 6-mm punch biopsies from dorsal skin
samples in TSK/þ and wild-type littermates (Figure 2c).
Although the collagen content in TSK/þ mice treated with
control protein was increased by 4.5-fold relative to that in
wild-type littermates (Po0.0001), BAFF-R-Ig reduced the
collagen content by 51% in TSK/þ mice (Po0.0001).
Collagen content was comparable between wild-type mice
with BAFF-R-Ig and those with control protein. BAFF-R-Ig did
not significantly affect the development of pulmonary
emphysema and cardiac hypertrophy in TSK/þ mice (data
not shown) (McGaha et al., 2001). Thus, BAFF-R-Ig reduced
skin fibrosis in TSK/þ mice.
BAFF antagonist modifies B-cell phenotypes
BAFF has a crucial role during the transitional type 1 (T1)–T2
transition (Gross et al., 2001; Schiemann et al., 2001), and
B-cell maturation is blocked at the T1 stage in mice that are
treated with BAFF antagonist (Gross et al., 2001; Schneider
et al., 2001). B-cell phenotypes in BAFF-R-Ig or control
protein-treated mice were examined at 8 weeks of age. B-cell
phenotypes in TSK/þ mice with control protein were similar
to wild-type littermates with control protein (Figure 3 and
Table 1). Total B cells were significantly decreased (B75%)
in spleen from TSK/þ and wild-type littermates with BAFF-R-
Ig. Concerning B-cell phenotypes, mature B cells in bone
marrow and spleen were significantly decreased by BAFF-R-
Ig treatment. In addition, BAFF-R-Ig attenuated T2, marginal
zone, and follicular B cells in both TSK/þ and wild-type
littermates. Conversely, T1 cells were significantly increased
by BAFF-R-Ig. Thus, BAFF antagonist modified B-cell
phenotypes in both TSK/þ and wild-type littermates.
BAFF antagonist inhibits autoantibody generation in TSK/þ
mice
Although a pathogenic role for autoantibodies in SSc
development remains uncertain (Zhou et al., 2005), autoanti-
body and serum Ig levels were assessed in TSK/þ mice
as markers for effective BAFF antagonist and hyperactivity.
TSK/þ mice with control protein produced significantly
higher levels of anti-topoisomerase I antibody when com-
pared to wild-type littermates with control protein (Po0.05;
Figure 4a). However, anti-topoisomerase I antibody (Ab)
levels were decreased significantly in TSK/þ mice with
BAFF-R-Ig relative to TSK/þ littermates with control protein
when assessed by ELISA (Figure 4a).
TSK/þ mice treated with control protein had significantly
elevated IgM and IgG2a levels compared to wild-type
littermates with control protein (Po0.05; Figure 4b). How-
ever, TSK/þ mice treated with BAFF-R-Ig had significantly
decreased IgM, IgG2a, IgG2b, and IgG3 levels compared to
TSK/þ littermates with control protein (Figure 4a). Thus,
BAFF antagonist inhibited the autoantibody production and
the development of hyper-g-globulinemia in TSK/þ mice.
BAFF antagonist downregulates augmented type 2 cytokines
expression in the skin of TSK/þ mouse
Cytokines are critical for the development of skin sclerosis in
TSK/þ mice (Ong et al., 1999; Tsuji-Yamada et al., 2001).
We assessed cytokine expression in the skin by real-time PCR
analysis. In the skin, TGF-b mRNA levels were elevated in
TSK/þ mice (2.1-fold) relative to wild-type littermates
(Po0.001; Figure 5). However, BAFF antagonist significantly
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Figure 2. Effect of BAFF antagonist on skin fibrosis in TSK/þ mice. Skin
fibrosis in dorsal skin from 8-week-old TSK/þ and wild-type littermates
treated with BAFF-R-Ig or Fc control protein (control). (a) Skin fibrosis was
assessed by quantitatively measuring hypodermal thickness. Representative
hematoxylin and eosin-stained histological sections. Dermis is indicated by
(d), hypodermis beneath the panniculus carnosus (arrow) indicated by (h).
Bar¼0.1 mm. These results represent those obtained with at least five mice of
each group. Skin fibrosis was assessed further by quantitatively measuring
(b) hypodermal thickness and (c) skin collagen content. Results from each
mouse are represented as single dots. Horizontal bars represent mean
hypodermal thickness or collagen content in each group.
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reduced TGF-b transcript levels in TSK/þ mice (Po0.005) to
1.2-fold of wild-type levels, but did not reduce TGF-b levels
in wild-type mice. IL-6 and IL-10 mRNA levels were
increased by 2.2-fold (Po0.01) and 2.1-fold (Po0.01),
respectively, in TSK/þ mice with control protein compared
to wild-type littermates with control protein (Figure 5). By
contrast, IFN-g mRNA levels were tend to be decreased in
TSK/þ mice with control protein compared with wild type
with control protein. However, BAFF antagonist significantly
reduced IL-6 and IL-10 mRNA levels in TSK/þ mice
(Po0.005). BAFF antagonist also significantly increased
IFN-g mRNA levels in TSK/þ mice (Po0.005), but not
wild-type mice. Thus, the skin from TSK/þ mice exhibited
augmented fibrogenic type 2 cytokines, such as IL-6 and
IL-10, expression that was downregulated by BAFF antagonist,
whereas BAFF antagonist upregulated IFN-g expression in the
skin from TSK/þ mice.
BAFF accelerates IL-6 production by TSK/þ B cells
Recent studies shed light on the B cells as cytokine-producing
cells (Lipsky, 2001; Mauri et al., 2003). We investigated the
role of BAFF in cytokine production by B cells. Splenic B cells
were stimulated with BAFF and/or Staphylococcus aureus
Cowan strain (SAC), and culture supernatants were analyzed
by ELISA to determine the amount of IL-6 and IL-10. B cells
stimulated with BAFF and SAC produced significant amount
of IL-6 and IL-10 (Figure 6). IL-6, but not IL-10, production
from TSK/þ B cells was significantly higher than those from
wild-type B cells in the presence of BAFF and SAC.
Furthermore, IL-6 and IL-10 production from B cells
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Figure 3. BAFF antagonist modifies B-cell phenotypes in TSK/þ mice. B-cell phenotypes in 8-week-old TSK/þ and wild-type littermates treated with BAFF-R-
Ig or Fc control protein (control). Bone marrow and spleen were collected, stained with fluorescently labeled mAbs to a variety of cell surface markers,
and analyzed by flow cytometry. Representative profiles are shown for bone marrow and B220þ spleen. (a) Bone marrow cells were stained with mAbs to IgM
and B220, to identify pro/pre (IgMB220low), immature (IgMþB220low), and mature B cells (IgMþB220high). (b) Splenic B cells (B220þ -gated) were stained with
mAbs, CD21, CD23, and CD24, to identify newly formed (NF; CD21CD23B220þ ), T1 (CD24highCD21 B220þ ), T2 (CD24highCD21þ B220þ ), follicular
(FO; CD21þ CD23þ B220þ ), and marginal zone (MZ) B cells (CD21highCD23 B220þ ).
Table 1. B-cell subsets in spleen
Wild type + control Wild type + BAFF-R-Ig TSK/ + + control TSK/ + + BAFF-R-Ig
B220+ B220+ 40.172.3 30.577.2** 41.474.2 31.576.5ww
T1 CD24highCD21 B220+ 15.573.3 55.577.2* 14.072.2 54.576.1w
T2 CD24highCD21+ B220+ 6.371.3 0.470.1* 6.571.1 0.570.2w
Marginal zone CD21highCD23 B220+ 5.771.0 1.970.7* 5.870.9 2.270.6w
Follicular CD21+ CD23+ B220+ 70.973.6 28.675.5* 72.072.4 30.475.7w
Values are mean percent7SD (n=5).
*Po0.01, **Po0.05 versus wild-type littermates treated with control protein, wPo0.01, wwPo0.05 versus TSK/+ littermates treated with control protein.
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stimulated with BAFF and SAC were attenuated by BAFF-R-Ig.
Thus, TSK/þ B cells had a significantly enhanced ability to
produce IL-6 by BAFF stimulation.
DISCUSSION
This is the early evidence to reveal roles of BAFF on the
development of skin fibrosis in TSK/þ mice. The dysregulation
of BAFF expression was shown in TSK/þ mice (Figure 1a).
Dramatically, the development of skin fibrosis in TSK/þ mice
was prevented by treatment with BAFF-R-Ig that blocks BAFF
(Figure 2). BAFF antagonist also inhibited the development of
hyper-g-globulinemia and the autoantibody production in TSK/þ
mice (Figure 4). TSK/þ skin showed upregulated expres-
sions of fibrogenic type 2 cytokines, such as IL-6 and IL-10,
whereas BAFF antagonist significantly suppressed them
(Figure 5). Reciprocally, BAFF antagonist augmented anti-
fibrogenic type 1 cytokines, IFN-g, in the skin of TSK/þ mice.
Furthermore, TSK/þ B cells with BAFF stimulation had a
significantly enhanced ability to produce IL-6 (Figure 6). These
results suggest that BAFF/BAFF-receptor system is critical for
the development of skin fibrosis in TSK/þ mice.
Previous studies have shown that B cells contribute to
disease pathogenesis in TSK/þ mice (Walker et al., 1989;
Phelps et al., 1993; Saito et al., 2002), although some studies
have concluded that B cells play no role in skin sclerosis
(Kasturi et al., 1997; Siracusa et al., 1998; Dodig et al., 2001).
The development of skin fibrosis correlated closely with
serum anti-topoisomerase I Ab levels in TSK/þ mice
(Hatakeyama et al., 1996). CD19-deficiency in TSK/þ mice
downregulates B-cell function, improves skin sclerosis, and
inhibits autoimmunity (Saito et al., 2002). In addition, we
have reported recently that B-cell depletion using anti-mouse
CD20 monoclonal antibody (mAb) significantly suppressed
the development of skin fibrosis, autoantibody production,
and hyper-g-globulinemia in TSK/þ mice (Hasegawa et al.,
2006). Depending on similar mechanism, BAFF antagonist
prevented the development of skin fibrosis in TSK/þ mice in
the current study. Despite downregulated skin fibrosis, the
development of lung emphysema was not affected by
blocking of BAFF in TSK/þ mice in the current study (data
not shown). Similar dissociation between cutaneous hyper-
plasia and lung emphysema has been reported in previous
studies (Wallace et al., 1994; McGaha et al., 2001; Saito
et al., 2002; Hasegawa et al., 2006).
Type 2 cytokines, but not type 1 cytokines, are critical for
the development of cutaneous fibrosis in TSK/þ mice (Ong
et al., 1999; McGaha et al., 2001; Kodera et al., 2002).
Consistent with these findings, cytokine balance was skewed
to type 2 cytokines rather than type 1 in the skin of TSK/þ
mice (Figure 5). Especially, IL-6 induces concentration-
dependent increases in the production of collagen and
glycosaminoglycans from human dermal fibroblasts in vitro
(Duncan and Berman, 1991). In addition, skin fibrosis in TSK/
þ mice is improved with a parallel decrease in IL-6
production from B cells (Saito et al., 2002). In the current
study, TSK/þ B cells with BAFF stimulation had a signifi-
cantly enhanced ability to produce IL-6 (Figure 6), and BAFF
antagonist suppressed those. Taken together, augmented IL-6
production by TSK/þ B cells with BAFF could play an
important role in the development of fibrosis, and BAFF
antagonist attenuated skin fibrosis in TSK/þ mice with
decrease in IL-6 production from B cells.
BAFF is an essential component of B-cell homeostasis and
a potent B-cell survival factor associated with systemic
autoimmune disease in animals (Mackay et al., 1999; Gross
et al., 2000; Khare et al., 2000). Previous studies have
provided strong evidence that constitutive BAFF overproduc-
tion in mice leads not only to polyclonal hyper-g-globuline-
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Figure 4. BAFF antagonist inhibits autoantibody generation and hyper-c-
globulinemia in TSK/þ mice. (a) Anti-topoisomerase I (topo I) Ab and
(b) antibody levels in sera from 8-week-old TSK/þ and wild-type littermates
treated with BAFF-R-Ig or Fc control protein (control). Relative serum
autoantibody and antibody levels were determined by Ig subclass-specific
ELISA. Horizontal bars represent mean autoantibody and antibody levels for
each group.
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mia, but also to spontaneous production of multiple
antoantibodies (Mackay et al., 1999; Gross et al., 2000;
Khare et al., 2000). Consistent with this, excess BAFF may
lead to the autoantibody production and the development of
hyper-g-globulinemia in TSK/þ mice, while it is not clear
why BAFF expression is higher in TSK/þ mice. A hypothesis
was proposed that altered fibrillin leads to increased TGF-b
activity in TSK/þ mice (Lemaire et al., 2006). Like this,
dysregulation of BAFF expression may be induced in TSK/þ
mice. It is intriguing but remains unsolved why serum BAFF
levels in TSK/þ mice return to wild-type levels by 12 weeks,
which may indicate that BAFF is essential for the develop-
ment of skin fibrosis during the early stage of disease, since
skin fibrosis in TSK/þ mice establishes until 12 weeks. While
we have not identified the factor(s) that induce elevated BAFF
levels in TSK/þ mice, we could hypothesize that the
‘‘fibrosis-BAFF loop’’ may exist in TSK/þ mice. Skin fibrosis
may activate BAFF-producing cells, such as macrophages,
dendritic cells, and T cells, and thereby induce BAFF
overproduction. Moreover, BAFF plays an important role in
the development of TSK/þ skin fibrosis via cytokine and
autoantibody productions from B cells, which have patho-
genic roles in fibrosis. Therefore, fibrosis and BAFF could
interact with each other in TSK/þ mice. Further studies will
be needed to prove this hypothesis formally.
The current study showed that the development of skin
fibrosis in TSK/þ mice was significantly attenuated by
treatment with BAFF antagonist. Consistent with the positive
results in the current study, critical roles of BAFF have also
been suggested in various autoimmune mouse models, such
as lupus-prone mouse (Gross et al., 2000; Kayagaki et al.,
2002; Ramanujam et al., 2006) and collagen-induced arthritis
(Gross et al., 2001; Wang et al., 2001). Moreover, treatment
with BAFF antagonists were already started in SLE patients
and showed safety and effectiveness (Baker et al., 2003; Furie
et al., 2003; Wallace et al., 2006). Until now, since few
therapies have proved to be effective for SSc in control
studies, TSK/þ mice could serve as a useful animal model for
assessing SSc thearpy. However, TSK/þ mice and human
scleroderma differs in many ways such as the sites of fibrosis
(Green et al., 1976). Therefore, we should be aware that
results from TSK/þ mice cannot be simply translated into
human therapies. Nonetheless, our findings suggest the
possibility that BAFF antagonist is a potential therapeutic
tool in human SSc.
MATERIALS AND METHODS
Mice
TSK/þ mice with a C57BL/6 genetic background were purchased
from The Jackson Laboratory (Bar Harbor, ME). To verify the TSK/þ
genotype, PCR amplification of a partially duplicated fibrillin 1 gene
was carried out using genomic DNA from each mouse as described
(McGaha et al., 2001). NZB/NZW F1 mice were purchased from
SLC Japan (Shizuoka, Japan). All mice were housed in a specific
pathogen-free barrier facility and screened regularly for pathogens.
Female mice were used in these experiments. The Committee on
Animal Experimentation of Kanazawa University Graduate School of
Medical Science approved all studies and procedures.
In vivo treatment
Murine BAFF-R-Ig (R&D Systems Inc., Minneapolis, MN), which
were made by fusing their extracellular domains to the Fc portion of
human IgG1 and neutralize murine BAFF, and Fc control protein
(Acris Antibodies, Hiddenhausen, Germany) were used in this study.
To neutralize BAFF in vivo, 1-week-old TSK/þ and wild-type
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Figure 5. BAFF antagonist downregulates augmented type 2 cytokines in TSK/þ skin. Messenger RNA expression of cytokines in dorsal skin from 8-week-old
TSK/þ and wild-type littermates treated with BAFF-R-Ig or Fc control protein (control). The mRNA levels of TGF-b1, IL-4, IL-6, IL-10, and IFN-g were analyzed
by real-time reverse transcriptase-PCR, and normalized with the internal control glyceraldehyde-3-phosphate dehydrogenase. Each sample was done in
triplicate. Data indicate the mean7SEM. These results represent those obtained with at least five mice of each group.
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Figure 6. BAFF accelerates IL-6 production by TSK/þ B cells. Splenic B cells
were purified by positive selection with anti-B220 Ab-coated magnetic beads
and were stimulated for 72 hours with either medium alone or recombinant
mouse BAFF and/or Staphylococcus aureus Cowan strain (SAC) and/or BAFF-
R-Ig. Culture supernatants were analyzed by ELISA to determine the amount
of IL-6 and IL-10.
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littermates received either murine BAFF-R-Ig (2mg/g intraperitonealy
3 times/week) or the same dose of Fc control protein.
Histopathological assessment of skin fibrosis
Morphologic characteristics of skin sections from TSK/þ and wild-
type littermates were assessed under a light microscope. All skin
sections were taken from the para-midline, lower back region (the
same anatomic site to minimize regional variations in thickness) as
full thickness sections extending down to the body wall musculature.
Tissues were fixed in 10% formaldehyde solution for 24 hours and
embedded in paraffin. Sections were stained with hematoxylin and
eosin. Hypodermal thickness, which was defined as the thickness of
a subcutaneous loose connective tissue layer (i.e., the hypodermis or
superficial fascia) beneath the panniculus carnosus, was measured
for multiple transverse perpendicular sections using an ocular
micrometer. Dermal thickness defined as the thickness of skin from
the top of the granular layer to the junction between the dermis and
subcutaneous fat was also examined. Ten random measurements
were taken per section. Two investigators in a masked fashion
examined all of the sections independently.
Determination of collagen content in the skin tissue
Collagen content was determined by harvesting 6-mm punch
biopsies from shaved dorsal skin samples. Skin samples were
homogenized by TissueLyser system (QIAGEN Ltd, Crawley, UK),
and then skin homogenate were assayed for collagen levels and
compared with a standard curve prepared from rat tail collagen
using the Sircol assay (Biocolor, Belfast, UK) according to the
manufacturer’s instructions. The assay was performed in duplicate,
and the mean of two data was determined for individual sample.
ELISA
Serum BAFF levels were measured by ELISA kit (Apotech, Epalinges,
Switzerland), according to the manufacturer’s protocol. For BAFF
assay, all sera were preabsorbed with protein A (Amersham
Biosciences, Piscataway, NJ) to deplete Ig. IL-6 and IL-10 concen-
trations in the culture medium were measured by ELISA, according
to the manufacturer’s protocols (BD Biosciences, San Jose, CA).
Mouse Ig concentrations in sera were determined by ELISA, using
affinity-purified mouse IgM, IgG1, IgG2a, IgG2b, and IgG3 (South-
ern Biotechnology Associates Inc., Birmingham, AL) to generate
standard curves as described (Engel et al., 1995). Anti-topoisomerase
I Ab levels were quantified using ELISA kits according to the
manufacture’s protocol (Medical & Biological Laboratories, Nagoya,
Japan). Each sample was tested in duplicate.
Flow cytometry
Cells were stained with the following Abs (obtained from BD
Biosciences, unless otherwise noted): IgM (R6-60.2), B220 (RA3-
6B2), CD21 (7G6), CD23 (B3B4), CD24 (M1/69), BAFF-R (7H22-
E16; ALEXIS, Lausen, Switzerland), TACI (166010; R&D Systems
Inc.), or BCMA (161616; R&D Systems Inc.). For two- or three-color
immunofluorescence analysis, single-cell lymphocyte suspensions
(1 106) were stained at 41C using predetermined optimal con-
centrations of mAb for 20 minutes as described (Sato et al., 1996).
Cells with the forward and side light scatter properties of
lymphocytes were analyzed on a FACScan flow cytometer (BD
Biosciences). Positive and negative populations of cells were
determined using unreactive isotype-matched mAbs (BD Bio-
sciences) as controls for background staining.
RNA isolation and real-time reverse transcriptase-PCR
Total RNA was isolated from deep-frozen full-thickness dorsal skin
sections or cultured dermal fibroblasts using QIAGEN RNeasy spin
columns (QIAGEN Ltd) and digested with DNaseI (QIAGEN Ltd) to
remove chromosomal DNA in accordance with the manufacturer’s
protocols. RNA was reverse transcribed into cDNA using the Reverse
Transcription System (Promega, Madison, WI). Transcript levels were
quantified using a real-time PCR method according to the
manufacturer’s instructions (Applied Biosystems, Foster City, CA).
Sequence-specific primers and probes were designed by Pre-
Developed TaqMans Assay Reagents or TaqMans Gene Expression
Assays (Applied Biosystems). Real-time PCR (one cycle of 501C for
2 minutes, 951C for 10 minutes; 40 cycles of 921C for 15 seconds,
601C for 60 seconds) was performed on an ABI Prism 7000 Sequence
Detector (Applied Biosystems). Glyceraldehyde-3-phosphate dehy-
drogenase transcript levels were used as controls to normalize
mRNA levels. The relative expression of target transcript PCR
products was determined using the DDCt method (Meijerink et al.,
2001). Fold induction¼ 2DDCt , where Ct¼ the threshold cycle, that
is the cycle number at which the sample’s relative fluorescence rises
above the background fluorescence and DDCt¼ [Ct gene of interest
(unknown samples) Ct glyceraldehyde-3-phosphate dehydrogenase
(unknown samples)][Ct gene of interest (calibrator samples)Ct
GAPDH (calibrator sample)]. Each sample was run in triplicate,
with the mean Ct used in the equation.
B-cell culture
Splenic B cells were purified by positive selection with anti-B220
Ab-coated magnetic beads (BD Biosciences) and resuspended in
RPMI-1640 medium containing 5% fetal calf serum. Purified B cells
(2 105/well) were cultured in 0.2 ml of culture medium in 96-well
flat-bottom plates for 72 hours with recombinant mouse BAFF (R&D
Systems Inc.), and/or SAC (Sigma, St Louis, MO), and/or murine
BAFF-R-Ig (R&D Systems Inc.).
Statistical analysis
Data are expressed as mean values7SEM. The Mann–Whitney
U-test was used for determining the level of significance of
differences between sample means and Bonferroni’s test was used
for multiple comparisons.
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